Clinicopathologic factors for central recurrence in patients with locally advanced bulky cervical cancer
- Authors
- Lee, Won-Moo; Park, Sang-Il; Kim, Beob-Jong; Kim, Moon-Hong; Choi, Seok-Cheol; Lee, Eui-Don; Ryu, Sang-Young
- Issue Date
- Apr-2012
- Publisher
- Elsevier BV
- Keywords
- Uterine cervical neoplasm; Recurrence; Local neoplasm recurrence; Adjuvant hysterectomy
- Citation
- European Journal of Obstetrics & Gynecology and Reproductive Biology, v.161, no.2, pp 219 - 223
- Pages
- 5
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- European Journal of Obstetrics & Gynecology and Reproductive Biology
- Volume
- 161
- Number
- 2
- Start Page
- 219
- End Page
- 223
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/165900
- DOI
- 10.1016/j.ejogrb.2011.12.029
- ISSN
- 0301-2115
1872-7654
- Abstract
- Objective: Locally advanced bulky cervical cancer (LABCC) is characterized by poor local control. The objective of this study was to identify the clinicopathologic variables associated with one-year central-only recurrence, which will serve as criteria for adjuvant hysterectomy after radiation (AHR) in patients with LABCC. Study design: Between January 2000 and August 2007, we retrospectively evaluated outcomes in 225 patients with LABCC who were initially treated with radiation or chemoradiation. Results: Among the 225 patients with LABCC, there were 41 recurrences within one year after treatment (8 central-only and 33 pelvis and/or distant site recurrences). Age, stage, and treatment type were not associated with the one-year central-only recurrences, but tumor size ≥8 cm had a statistically significant association based on multivariate analysis (OR, 5.39; 95% CI, 1.15-25.31; p = 0.03). The combination of non-squamous cell (non-SCC) type and tumor size ≥8 cm had a significantly higher rate of recurrence within one year (OR, 43.0; 95% CI, 4.78-386.68; p < 0.01). Conclusions: Of patients with LABCC, those with non-SCC tumors ≥8 cm in size were at high risk for early central-only recurrence after cisplatin-based chemoradiation, and represent the subset of patients for whom AHR is beneficial.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 서울 의과대학 > 서울 산부인과학교실 > 1. Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.